The GOLGA7 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population designed for loss-of-function studies of the GOLGA7 gene, which encodes the Golgi-associated golgin A7 protein. This genetically defined tool enables researchers to dissect the contributions of GOLGA7 to Golgi architecture and vesicular trafficking. As a polyclonal pool, it circumvents clonal selection biases and more closely mimics the genetic heterogeneity of natural cell populations, allowing robust and reproducible phenotypic analyses. By disrupting GOLGA7, the model permits investigation of downstream effects on secretory pathway integrity and inter-organelle communication.
The parental HAP1 cell line originates from the near-haploid KBM-7 chronic myeloid leukemia line. Its fibroblast-like morphology and haploid genome simplify genetic manipulation; a single-copy gene disruption reliably leads to a functional null phenotype without the confounding influence of a second allele. HAP1 cells retain a fully operational membrane trafficking system, including a well-characterized Golgi apparatus, making them an ideal chassis for studying organelle dynamics. High proliferation and compatibility with high-throughput screening formats further enhance their utility in functional genomics and drug discovery campaigns.
GOLGA7 localizes to the cis-Golgi and functions as a tethering factor, interacting with core Golgi matrix proteins such as GOLGA2 (also known as GM130) and the vesicle-docking protein p115 (USO1). Its membrane recruitment is driven by active RAB GTPases, especially RAB1, and regulated by ARF GTPases, notably ARF1, which coordinate COPI vesicle budding. GOLGA7 works in concert with the conserved oligomeric Golgi (COG) complex to facilitate SNARE-mediated vesicle fusion. The mechanistic model posits that GOLGA7 maintains the structural continuity of the Golgi ribbon and ensures bidirectional protein transport between the ER and the Golgi. Disruption of GOLGA7 leads to Golgi fragmentation, defective tethering of COPI vesicles, and impaired secretion of cargo proteins.
Within the HAP1 background, loss of GOLGA7 produces a clear phenotype that can be readily visualized by immunofluorescence staining of Golgi markers such as GM130 or giantin. The haploid state guarantees that phenotypes are not diluted by wild-type alleles, yielding decisive results in trafficking assays. Researchers can employ GFP-tagged RAB proteins to monitor dynamic vesicle transport or use flow cytometry to quantify changes in surface receptor levels. This model is particularly relevant for studying diseases like cancer, where altered secretion and glycosylation contribute to tumor progression, and autoimmune disorders, where abnormal antigen presentation may involve Golgi dysfunction.
This polyclonal knockout cell product is designed for a wide array of experimental approaches, including super-resolution microscopy to examine Golgi ultrastructure, biochemical fractionation to assess protein trafficking intermediates, and mass spectrometry-based secretome analysis to identify altered secretory profiles. It is compatible with functional genomics screens to uncover genetic interactions and chemical perturbations that rescue or exacerbate the knockout phenotype. For further information or to discuss applications, please contact Ascent Research.
